English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

mistake the higherand lower-dosed edoxaban groups for the 60 mg and 30 mg groups, respectively. The safety outcomes of 350 patients who received only edoxaban 60 mg were not shown at any point. On-treatment analyses concentrate on compliant patients so that the biological effects of the treatment can be studied.7 The safety outcomes should be re-analyzed on-treatment, and the data, including rates of intracranial bleeding and gastrointestinal bleeding of patients who received a dose reduction, should be disclosed in Table 5. Furthermore, in Table 3, describing the efficacy in patients who received a dose reduction, details of stroke (those who experienced ischemic or hemorrhagic stroke) should be also disclosed. I hope the study is re-evaluated and the new safety outcomes are found to be nearly the same because an edoxaban dose of 60 mg once daily has been approved for treatment of AF patients in East Asia, and the issue of necessity for DOACs dosage adjustment in East Asia will arise. Lastly, Table 2 showed that in the East Asian population, among the warfarin group, the number of patients who experienced hemorrhagic stroke was 18 and the number who experienced ischemic stroke was 19, but the total was 36. Why is this? A similar anomaly is shown among the edoxaban higherdosed group. Is it right for us to conclude that in each case, 1 patient suffered from hemorrhagic infarct (ischemic stroke complicated with hemorrhage) among the warfarin and edoxaban higher-dosed group in the East Asian population, respectively?

Has the Safety of Edoxaban 60 mg Among East Asian Atrial Fibrillation Patients Been Truly Proven by the ENGAGE AF-TIMI 48 Subanalysis?